Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

NCT06774079 on ClinicalTrials.gov · last registry update 2026-03-30

A small phase 4 — 24 participants, against a typical 75. Due to report 5 March 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Change in percentage of participants retained. Sponsors move these dates routinely; any movement since this site started watching is listed below.

Status: RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: University of Miami
Sponsor type: Other
Enrollment: 24
Started: 2025-03-05
Primary completion: 2027-03-05 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in percentage of participants retained

Conditions studied

Crohn Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.